Literature DB >> 21084254

Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma.

J Ambroszkiewicz1, J Gajewska, T Klepacka, M Chełchowska, T Laskowska-Klita, W Woźniak.   

Abstract

PURPOSE: Biochemical markers of bone turnover reflecting the intensity of all bone remodeling processes in skeleton are important for fast and non-invasive assessment of bone formation and resorption processes. They can be used in terms of both physiological and pathological states. The aim of this study was to investigate if bone metabolism markers can be clinically useful for monitoring of treatment in children and adolescents with osteosarcoma. MATERIAL/
METHODS: The study consisted of 55 patients (median age 15 years) with osteosarcoma and 60 healthy age matched counterparts. Serum bone turnover markers (bone alkaline phosphatase - BALP, osteocalcin - OC and C-terminal telopeptide of type I collagen - CTX) were analyzed by immunoenzymatic methods in patients at time of diagnosis, during treatment and after therapy.
RESULTS: We observed that before treatment the concentration of OC in patients with osteosarcoma was significantly lower (p<0.05) compared to that obtained in healthy children, however, BALP and CTX were at a similar level. During chemotherapy the values of bone formation and resorption markers significantly decreased by about 20-30%. After therapy we observed different concentrations of all bone turnover markers in patients with favorable and unfavorable prognosis. Median values of OC and BALP were over twofold higher in patients with progression as compared to patients with remission of disease (p<0.01 and p<0.001, respectively). Patients with poor prognosis had also higher serum concentration of bone resorption marker in comparison to patients with remission (p<0.01).
CONCLUSIONS: Presented results suggest that bone turnover markers identify changes in bone metabolism in patients with osteosarcoma during anticancer therapy. These markers due to the non-invasive methods and their specificity might be useful in monitoring of clinical treatment of osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084254     DOI: 10.2478/v10039-010-0043-2

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  16 in total

1.  Role of β-isomerized C-terminal telopeptides (β-CTx) and total procollagen type 1 amino-terminal propeptide (tP1NP) as osteosarcoma biomarkers.

Authors:  Tu Hu; Qingcheng Yang; Jing Xu; Zhichang Zhang; Nengbin He; Yuzhen Du
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis.

Authors:  H Zhu; H Cai; M Tang; J Tang
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

3.  Salvianolic acid B suppresses cell proliferation and induces apoptosis in osteosarcoma through p38-mediated reactive oxygen species generation.

Authors:  Zhaoyang Zeng; Hua Zhang; Xin Wang; Kai Liu; Tian Li; Shaobo Sun; Hailong Li
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

4.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.

Authors:  L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein
Journal:  Vet Comp Oncol       Date:  2015-02-03       Impact factor: 2.613

5.  Gene expression profiles resulting from stable loss of p53 mirrors its role in tissue differentiation.

Authors:  Oliver Couture; Eric Lombardi; Kendra Davis; Emily Hays; Nalini Chandar
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

6.  Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.

Authors:  Bo Wang; Jian Tu; Junqiang Yin; Changye Zou; Jin Wang; Gang Huang; Xianbiao Xie; Jingnan Shen
Journal:  Oncotarget       Date:  2015-11-10

7.  Serum tumor markers in pediatric osteosarcoma: a summary review.

Authors:  Yulia A Savitskaya; Genaro Rico-Martínez; Luis Miguel Linares-González; Ernesto Andrés Delgado-Cedillo; René Téllez-Gastelum; Alfonso Benito Alfaro-Rodríguez; Antonio Redón-Tavera; José Clemente Ibarra-Ponce de León
Journal:  Clin Sarcoma Res       Date:  2012-03-23

8.  High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China.

Authors:  Ju Han; Bicheng Yong; Canqiao Luo; Pingxian Tan; Tingsheng Peng; Jingnan Shen
Journal:  World J Surg Oncol       Date:  2012-02-15       Impact factor: 2.754

9.  SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA.

Authors:  Juan Pablo Zumárraga; André Mathias Baptista; Luis Pablo De La Rosa; Marcelo Tadeu Caiero; Olavo Pires De Camargo
Journal:  Acta Ortop Bras       Date:  2016 May-Jun       Impact factor: 0.513

Review 10.  Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data.

Authors:  Hai-Yong Ren; Ling-Ling Sun; Heng-Yuan Li; Zhao-Ming Ye
Journal:  Biomed Res Int       Date:  2015-11-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.